At ScreeningPort, we are pioneering a cost-effective, scalable ‘Discovery
Solution’ for the European biomedical research community. Our goal is to transform the exciting new science, taking place at the benchtops of Europe’s academic laboratories, into chemical tools and high quality assets of explicit value to potential major Pharma partners and - ultimately - to patients. 

The inputs at ScreeningPort are novel or under-exploited therapeutic  targets with great potential, but which are unattractive to Pharma because they may lack either tractable lead series or supporting clinical proof of concept (PoC) data. Outputs range from tool compounds for mechanistic studies and PoC programs, through to high quality drug-like lead compounds suitable for progression to the pre-clinical candidates stage.